Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours

British Journal of Cancer

Volumn 101, Issue 1, 2009, Pages 55-63

  Hussein, D ^a   Holt, S V ^a   Brookes, K E ^a   Klymenko, T ^a   Adamski, J K ^a   Hogg, A ^a   Estlin, E J ^b   Ward, T ^a   Dive, C ^a,c   Makin, G W J ^a,b,c,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Childhood cancer; Ewing's sarcoma; Neuroblastoma; Novel therapies; Osteosarcoma

Indexed keywords

2,5 DIAZIRIDINYL 3 [HYDROXYMETHYL] 6 METHYL 1,4 BENZOQUINONE; 2,6 DICHLOROPHENOLINDOPHENOL; ALKYLATING AGENT; CISPLATIN; DOXORUBICIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG; 2,5 DIAZIRIDINYL 3 (HYDROXYMETHYL) 6 METHYL 1,4 BENZOQUINONE; 2,5-DIAZIRIDINYL-3-(HYDROXYMETHYL)-6-METHYL-1,4-BENZOQUINONE; ANTINEOPLASTIC AGENT; AZIRIDINE DERIVATIVE; BENZOQUINONE DERIVATIVE; DIPHTHERIA TOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CHILDHOOD CANCER; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA CROSS LINKING; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; EWING SARCOMA; HUMAN; HUMAN CELL; IC 50; MOUSE; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BONE TUMOR; CELL GROWTH; CHILD; DRUG EFFECT; DRUG SCREENING; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AZIRIDINES; BENZOQUINONES; BONE NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHILD; CISPLATIN; DIPHTHERIA TOXIN; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NAD(P)H DEHYDROGENASE (QUINONE); NEUROBLASTOMA; OSTEOSARCOMA; SARCOMA, EWING'S; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67649884666     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605100     Document Type: Article

References (34)

1. Beall HD, Murphy AM, Hargreaves RHJ, Butler J, Ross D (1995) Nicotinamide adenine dinucleotide (phosphate):quinine oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinine cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 48:499-504
2. Begleiter A, Leith MK, Patel D, Hasinoff BB (2007) Role of NADPH cytochrome P450 reductase in activation of RH1. Cancer Chemother Pharmacol 60:713-723
3. Berardini MD, Souhami RL, Lee CS, Gibson NW, Butler J, Hartley JA (1993) Two structurally related diaziridinylbenzoquinones preferentially crosslink DNA at different sites upon reduction with DT-diaphorase. Biochemistry 32: 3306-3312
4. Bligh HF, Bartoszek A, Robson CN, Hickson ID, Kasper CB, Beggs JD, Wolf CR (1990) Activation of mitomycin C by NADPH:cytochrome p-450 reductase. Cancer Res 50:7789-7792
5. Brown JM, Giaccia AJ (1998) The unique physiology of solid tumours: opportunities and problems for cancer therapy. Cancer Res 58: 1408 - 1416
6. Chen HH, Ma JX, Forrest GL, Deng PS, Martino PA, Lee TD, Chen S (1992) Expression of rat liver NAD(P)H:quinone-acceptor oxidoreductase in Escherichia coli and mutagenesis in vitro at Arg-177. Biochem J 284:855 - 860
7. Chou TC, Talalay P (1977) A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 252:6438 - 6442
8. Chou TC, Motzer RJ, Tong Y, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Ins t 86: 1517- 1524
9. Chou TC, Hayball M (1996) CalcuSyn: Windows software for dose effect analysis. Biosoft: Cambridge (UK)Cresteil T, Jaiswal AK (1991) High levels of expression of the NAD(P)H:-quinine oxidoreductase (NQ01) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol 42:1021 - 1027
10. Cummings J, Spanswick VJ, Tomasz M, Smyth JF (1998) Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme directed bioreductive drug development. Biochem Pharmacol 56:405 - 414
11. Cummings J, Ritchie A, Butler J, Ward TH, Langdon S (2003) Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts. Anticancer Res 23:3979- 3983
12. Danson S, Johnson P, Ward T, Dawson M, Denneny O, Watson A, Jowle D, Sharpe P, Dive C, Ranson M (2007a) Final results of a phase 1 clinical trial of the bioreductive drug RH1. J Clin Oncol 25:18S, Abstract 2514
13. Danson S, Ranson M, Denneny O, Cummings J, Ward TH (2007b) Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase 1 clinical trial. Cancer Chemother Pharmacol 60: 851 - 861
14. Dehn DL, Winski SL, Ross D (2004) Development of a new isogenic cell- xenograft system for evaluation of NAD(P)H:quinone oxidoreductase- directed antitumor quinones: evaluation of the activity of RH1. Clin Cancer Res 10:3147-3155
15. Dehn DL, Inayat-Hussain SH, Ross D (2005) RH1 induces cellular damage in an NAD(P)H:quinine oxidoreductase 1-dependent manner: relationship between DNA cross-linking, cell cycle perturbations and apoptosis. J Pharmacol Exp Ther 313:771 - 779
16. Digby T, Leith MK, Thliveris JA, Begleiter A (2005) Effect of NQ01 induction on the antitumour activity of RH1 in human tumors in vitro and in vivo. Cancer Chemother Pharmacol 56:307 -316
17. Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani M (2005) Childhood cancer survival trends in Europe. J Clin Oncol 23:3742 - 3751
18. Gibson NW, Hartley JA, Butler J, Siegel D, Ross D (1992) Relationship between DT-diaphorase-mediated metabolism of a series of aziridinyl- bezoquinones and DNA damage and toxicity. Mol Pharmacol 42: 531 - 536
19. Hodnick WF, Sartorelli AC (1993) Reductive activation of mitomycin C by NADH:cytochrome b5 reductase. Cancer Res 53:4907-4912
20. Hussein D, Estlin EJ, Dive C, Makin GWJ (2006) Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther 5:2241-2250
21. 123I-metaiodobenzylguanidine scan correlates with event free survival in high risk neuroblastoma. J Clin Oncol 22:3909-3915
22. Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oie HK, Chan DC, Bunn PA, Mabry M, Dykes DJ, Harrison SD, Ross D (1992) Elevated DT- diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumour xenografts to mitomycin C. Cancer Res 52:4753-4757
23. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis- retinoic acid. New Engl J Med 341:1165-1173
24. Phillips RM, Naylor MA, Jaffar M, Doughty SW, Everett SA, Breen AG, Choudry GA, Stratford IJ (1999) Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships. J Med Chem 42:4071-4080
25. Sartorelli AC (1988) Therapeutic attack of hypoxic cells of solid tumours. Cancer Res 48:775 - 778
26. Sharp SY, Kelland LR, Valenti MR, Brunton LA, Hobbs S, Workman P (2000) Establishment of an isogenic human colon tumor model for NQ01 expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. Mol Pharmacol 58: 1146-1155
27. Siegel D, Gibson NW, Preusch PC, Ross D (1990) Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced damage and cytotoxicity in human colon carcinoma cells. Cancer Res 50:7483 - 7489
28. Traver RD, Horikoshi T, Danenberg KD, Stadlbauer TH, Danenberg PV, Ross D, Gibson NW (1992) NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 52:797 - 802
29. Tudor G, Alley M, Nelson CM, Huang R, Covell DG, Gutierrez P, Sausville EA (2005) Cytotoxicity of RH1:NAD(P)H:quinine acceptor oxidoreduc-tase (NQ01)-independent oxidative stress and apoptosis induction. Anti- Cancer Drugs 16:381-391
30. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1:1112 - 1116
31. Ward TH, Haran MS, Whittaker D, Watson AJ, Howard TD, Butler J (1995) Cross-resistance studies on two K562 sublines resistant to diaziridinyl- benzoquinones. Biochem Pharmacol 50:459- 464
32. Ward TH, Danson S, McGown AT, Ranson M, Coe NA, Jayson GC, Cummings J, Hargreaves RH, Butler J (2005) Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6- methyl-1,4-benzoquinone. Clin Cancer Res 11:2695- 2701
33. Winski SL, Hargreaves RHJ, Butler J, Ross D (1998) A new screening system for NAD(P)H:quinine oxidoreductase (NQ01)-directed antitumour quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQ01-directed antitumor agent. Clin Cancer Res 4:3083- 3088
34. Yan C, Kepa JK, Siegel D, Stratford IJ, Ross D (2008) Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumour agent RH1. Mol Pharm 74(6): 1657-1665